Abstract
WITHIN the past two years reports dealing with the supposed value of tolbutamide in acne,1 paralysis agitans2 and multiple sclerosis3 have appeared. It was to be expected that these reports would result in a more widespread use of tolbutamide in nondiabetic subjects, and that such a use, if attended by untoward effects, would have its repercussions in the literature of the next few years. Already, Schwartz4 and Yonet and Ballard5 have reported cases of tolbutamide-induced hypoglycemia in patients being treated for Parkinson's disease.† In these cases the blood sugar was found to be 30 and 40 mg. per 100 ml. . . .